Abstracts, ELCC 2016 -Metastases to and from the lung S145 outcome (0.38, 0.9, and 0.3). However, on multivariate analysis, pleural effusion and brain mets significantly impacted outcome (p = 0.09, 0.0008).
investigated the potential use of COX-2 inhibitors in cancer proliferation and apoptosis. Methods: Celecoxib, rofecoxib, etoricoxib, meloxicam, ibufrofen and indomethacin are the COX-2 inhibitors included in this study. Docetaxel and Cisplatin are the chemotherapeutic agents that we combined with COX-2 inhibitors. Lung cancer cell lines (NCI-H1048-Small cell lung cancer, A549-Non-small cell lung cancer) were purchased from ATCC LGC Standards. At indicated timepoint, following 24h and 48h incubation, cell viability and apoptosis were measured with Annexin V staining by flow cytometry. Statistical analysis was performed by GraphPad Prism (version 6). Results: In Small cell lung cancer cells, following 24h incubation, combinations of docetaxel and meloxicam, docetaxel and ibuprofen, docetaxel and indomethacin, showed increased apoptosis when compared to docetaxel alone (p<0.0001). In Non-small cell lung cancer cells, the 24h incubation was not enough to induce satisfactory apoptosis, but following 48h incubation, docetaxel plus indomethacin showed more cytotoxicity when compared to docetaxel alone (p<0.0001). In addition, the combination of cisplatin plus indomethacin was the only combination to be found with higher cytotoxicity when compared to cisplatin alone after 48h treatment (p<0.0001). Conclusion: Depending on the drug, the synergistic effect of COX-2 inhibitors plus chemotherapeutic agents has been demonstrated in lung cancer. Our suggestion is that COX-2 inhibitors could be used as additive and maintenance treatment in combination to antineoplastic agents in lung cancer patients.
treatment seemed to improve outcome. Whilst lacking QOL data and a supportive care control group, our data would suggest that for selected patients, especially those of good PS there remains a role for WBRT in NSCLC.Conclusion: Brain metastasis stability has significant impact on HUS in lung cancer patients. Treatment modalities of brain metastases may also impact HUS. Data collection is ongoing; updated HUS data including longitudinal assessments and multivariable analyses will be presented.
23%), or more (52%) cycles of chemotherapy. Physician assessed RR was 68% (PR 61%, CR 7%) and 16% of patients progressed during first-line therapy. Thoracic radiation (TRT) was given to 112 (49%) of patients (LS 87%, ES 27%). Patients with brain metastases at diagnosis, or progressing during first-line chemotherapy were not considered eligible for PCI. Among 156 eligible patients, 80 (51%) received PCI (LS 64%, ES 39%). Forty-one patients (26.3%) declined PCI. The median overall survival for all patients was 11.1m (LS 21.7m, ES 8.9m). Relapse occurred in 167 (73%) of patients: CNS alone 8.7%, CNS plus systemic relapse (13.1%), thoracic (28%), extrathoracic (9%), thoracic/extra-thoracic (14%). Median time to any relapse was 9.2m (LS 14.3m, ES 7.5m), while median time to CNS relapse was 6.9m (PCI given 6.2m, PCI not given 4.4m). Among 50 patients with CNS relapse, 16 received PCI (LS 9, ES 7) and 34 did not (LS 8, ES 26). Among 64 patients with thoracic relapse, 31 received TRT (LS 19, ES 12) and 33 did not (LS 5, ES 28).Conclusion: Only 50% of eligible SCLC patients receive PCI. CNS relapse occurs frequently and more commonly in patients who do not receive PCI. Implementation of PCI in routine clinical practice appears to influence patterns of recurrence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.